mitochondrial peptide - OPS Peptide Science

Peptide Education, Product Pillars, Research Protocols

SS-31: Complete Research Guide to the Mitochondrial Membrane Peptide

Posted on June 1, 2026June 1, 2026 by admin

01
Jun

Research Use Only Notice: SS-31 (Elamipretide) is a research peptide intended for in-vitro and animal research applications only. While it has been studied in clinical trials internationally, it is not FDA-approved as a drug. Nothing in this article constitutes medical advice, treatment recommendation, or guidance for human consumption.

SS-31 — also known as Elamipretide — is a small synthetic peptide that targets the inner mitochondrial membrane through cardiolipin binding. Unlike most research peptides that act on cell-surface receptors, SS-31 acts at the structural level of mitochondria themselves, stabilizing membrane architecture and improving electron transport chain efficiency. This unique mechanism has made SS-31 one of the most actively studied compounds in mitochondrial dysfunction research, with applications spanning cardiac disease models, neurodegeneration research, and broader mitochondrial biology. This complete guide from the chemistry team at OPS Peptide Science walks through what SS-31 is, how the cardiolipin binding mechanism works, and how it complements MOTS-c in mitochondrial research.

For the foundational research-workflow protocols, see our companion guides on how to reconstitute peptides, how to inject peptides, and peptide storage and refrigeration.

What Is SS-31?

SS-31 is a small synthetic peptide designed to selectively accumulate in mitochondria, where it binds cardiolipin — a phospholipid unique to the inner mitochondrial membrane. The “SS” prefix refers to the Szeto-Schiller research lineage where the compound was developed. The compound has also been called Bendavia in some clinical research contexts and Elamipretide as its International Nonproprietary Name (INN).

Key facts about SS-31:

Chemical class — 4-amino-acid synthetic peptide with modified aromatic residues
Molecular weight — approximately 640 Da
Sequence — D-Arg-2′,6′-dimethyltyrosine (Dmt)-Lys-Phe-NH2
Developer — Stealth BioTherapeutics
Half-life — approximately 2 hours
Form — typically supplied as lyophilized powder; reconstituted with bacteriostatic water
Clinical trial status — has been studied in Phase 2 and 3 trials for cardiovascular indications; not yet FDA-approved

What distinguishes SS-31 from most research peptides is its mechanism of action. While most peptides work by binding extracellular receptors and triggering downstream signaling cascades, SS-31 crosses cell membranes, accumulates in mitochondria specifically, and acts on the inner mitochondrial membrane structure directly. This is a different mechanistic category than the receptor agonist peptides that dominate most research catalogs.

SS-31 Structure and Chemistry

The SS-31 structure was engineered specifically for mitochondrial targeting:

D-amino acid at position 1 — D-arginine prevents enzymatic degradation
Modified tyrosine (Dmt) at position 2 — 2′,6′-dimethyltyrosine provides aromatic character important for mitochondrial accumulation
Positively charged residues — the arginine and lysine carry positive charges that drive mitochondrial accumulation (mitochondria have a strong negative membrane potential)
C-terminal amide — protects against C-terminal degradation
Small size — only 4 amino acids; small enough to cross membranes through passive mechanisms

The combination of small size, positive charge, and aromatic residues makes SS-31 unusually efficient at penetrating cell membranes and concentrating in mitochondria — typically achieving 1000-fold or higher concentrations in mitochondria compared to surrounding cytoplasm.

How SS-31 Works in Research (Cardiolipin Binding Mechanism)

The SS-31 mechanism centers on cardiolipin — a phospholipid found exclusively in the inner mitochondrial membrane. Cardiolipin has several critical functions:

Stabilizes electron transport chain complexes — Complexes I, III, IV, and V all require cardiolipin for proper assembly and function
Maintains inner membrane curvature — cardiolipin’s unique structure helps form the cristae folds that increase mitochondrial surface area
Participates in apoptosis signaling — cardiolipin oxidation triggers cytochrome c release in programmed cell death
Declines with age and disease — cardiolipin levels and integrity decrease in mitochondrial dysfunction

SS-31 binds cardiolipin and produces several documented effects:

Membrane stabilization — protects cardiolipin from oxidative damage
Improved electron transport efficiency — enhances Complex I, III, and IV function in research models
Reduced ROS production — improved electron flow means less electron leakage and reactive oxygen species generation
ATP production support — better-functioning electron transport chain produces more ATP per oxygen consumed
Reduced mitochondrial swelling — protects against permeability transition pore opening

The mechanism is structural rather than signaling-based — SS-31 doesn’t activate or inhibit receptors. It supports the mechanical and chemical environment that mitochondria need to function efficiently. The published SS-31 and Elamipretide research literature on PubMed documents these mechanisms across hundreds of studies.

SS-31 Research Applications

Cardiac Research

The largest body of SS-31 research focuses on cardiac applications. Animal models of heart failure, ischemia-reperfusion injury, and cardiac dysfunction have documented SS-31 effects on cardiac function markers, ejection fraction, and survival endpoints. SS-31 has been studied in human cardiovascular clinical trials internationally — though not yet FDA-approved for cardiac indications. Current trial status is tracked on ClinicalTrials.gov.

Neurodegeneration Research

Mitochondrial dysfunction is implicated in Alzheimer’s, Parkinson’s, and other neurodegenerative diseases. SS-31 research extends into these models — measuring effects on neuronal mitochondrial function, ROS markers, and neurodegeneration progression in animal research.

Mitochondrial Disease Research

SS-31 has been studied in genetic mitochondrial disease models — Barth syndrome, Leber’s hereditary optic neuropathy, and other primary mitochondrial dysfunctions. The cardiolipin binding mechanism is particularly relevant to Barth syndrome, where cardiolipin metabolism is genetically disrupted.

Skeletal Muscle Research

Aging-related muscle dysfunction (sarcopenia) involves declining mitochondrial function. Research has documented SS-31 effects on muscle mitochondrial function, ATP production, and exercise performance markers in animal aging models.

Kidney Research

Renal ischemia-reperfusion injury, acute kidney injury, and chronic kidney disease research models have used SS-31 to study mitochondrial dysfunction contributions to kidney pathology.

Eye Research

Age-related macular degeneration and other retinal diseases involve mitochondrial dysfunction. SS-31 research extends into ophthalmologic models studying mitochondrial protection in retinal cells.

SS-31 vs MOTS-c: Mitochondrial Peptide Comparison

Both SS-31 and MOTS-c target mitochondria, but through completely different mechanisms:

Property	SS-31	MOTS-c
Size	4 amino acids	16 amino acids
Origin	Synthetic design	Mitochondrial DNA encoded
Mechanism	Structural (cardiolipin binding)	Signaling (AMPK activation)
Target	Inner mitochondrial membrane	Multiple cellular pathways
Acute effects	Mitochondrial function within hours	Gene expression over days
Primary research focus	Cardiac, neurodegeneration	Metabolic, insulin sensitivity
Clinical trial history	Yes (cardiovascular)	Limited

The two compounds are complementary rather than redundant. SS-31 provides structural mitochondrial support; MOTS-c provides metabolic and gene expression effects. Research designs studying broad mitochondrial biology sometimes use both compounds to cover different aspects of mitochondrial dysfunction.

SS-31 Dosing in Research Models

SS-31 dosing in published research varies by study design:

Subcutaneous administration — most common route in animal research
Intravenous administration — used in cardiac research and clinical trials
Daily dosing — short half-life supports once-daily protocols in most published research
Dose ranges — typically reported in mg/kg body weight in animal research; clinical trials have used various dose levels
Study duration — most pre-clinical studies run 4-12 weeks; some long-term studies extend to 6 months

Research protocols should reference published methodology for the specific model. Cardiac research uses different dosing patterns than neurodegeneration research, and animal model species affect optimal protocols significantly. For broader effect-timeline context, see our guide on how long does it take for peptides to work.

SS-31 Storage and Stability

SS-31 stability follows standard small-peptide patterns, with one notable advantage — its D-amino acid and modified tyrosine residues provide better-than-average stability:

Storage Condition	Form	Stability Window
-80°C	Lyophilized powder	3-5+ years
-20°C	Lyophilized powder	18-24 months
2-8°C	Lyophilized powder	6-12 months
2-8°C	Reconstituted in BAC water	21-28 days
Room temperature	Lyophilized powder	2-4 weeks for transit

For practical storage protocols, see our companion guide on how long do peptides last at room temperature.

How to Identify Quality Research-Grade SS-31

SS-31’s modified amino acids (D-arginine, dimethyltyrosine) make synthesis technically demanding. Quality criteria for research-grade SS-31:

99%+ HPLC-MS verified purity — synthesis with modified amino acids produces measurable side products requiring careful purification
Per-lot Certificate of Analysis — each batch independently tested
Mass spectrometry identity confirmation — confirms molecular weight matches SS-31 (~640 Da)
Stereochemistry verification — confirms D-amino acid configurations are correct
Chain-of-custody documentation — traceable from manufacturer through fulfillment
Properly lyophilized appearance — clean white cake at the bottom of the vial
Research-use-only labeling — required by US regulations

At OPS Peptide Science, every SS-31 vial ships with a unique BIOVIRIDIAN COA code. Customers can verify the Certificate of Analysis for their specific lot — confirming purity and identity before opening the vial.

SS-31 Regulatory Status

Not FDA-approved — clinical trials have been conducted but no US drug approval as of this writing
Clinical trial history — Phase 2 and 3 trials in cardiovascular indications; mixed results have informed protocol refinement
Legal as research chemical — sold in the US for in-vitro and animal research under research-use-only labeling
Not WADA-prohibited as of current updates
Not DEA-scheduled — no controlled substance status

For the complete legal framework around research peptides like SS-31, see our detailed guide on are peptides illegal.

FAQ

What is SS-31?

SS-31 is a 4-amino-acid synthetic peptide also known as Elamipretide. It targets the inner mitochondrial membrane through cardiolipin binding, stabilizing membrane structure and improving electron transport chain function. It is one of the most actively studied compounds in mitochondrial dysfunction research.

Is SS-31 the same as Elamipretide?

Yes — SS-31 is the original research nomenclature; Elamipretide is the International Nonproprietary Name (INN) used in clinical trials and pharmaceutical contexts. The compound has also been called Bendavia in some clinical research. All three names refer to the same molecule.

How does SS-31 differ from other mitochondrial supplements?

Most mitochondrial supplements (CoQ10, PQQ, NAD+ precursors) work by providing electron transport chain cofactors. SS-31 works differently — it binds cardiolipin in the inner mitochondrial membrane, stabilizing the structural environment that the electron transport chain operates within. The mechanism is structural rather than substrate-based.

Is SS-31 FDA-approved?

No. SS-31 has been studied in Phase 2 and 3 clinical trials for cardiovascular and mitochondrial disease indications but has not received FDA approval. It is sold legally in the US as a research chemical under research-use-only labeling for in-vitro and animal research.

How long does it take SS-31 to show effects in research?

Mitochondrial function effects appear within hours in cell culture research and within days in animal research models. Tissue-level cardiac and neurological endpoints typically require 4-12 weeks of consistent dosing protocols to demonstrate measurable effects.

Can SS-31 be combined with MOTS-c in research?

Combination research is possible because the two compounds act through different mechanisms — SS-31 structurally at the mitochondrial membrane, MOTS-c through AMPK signaling and gene expression. Research designs studying broad mitochondrial biology sometimes use both compounds to cover complementary aspects. Specific combination protocols should be informed by published methodology references.

Where can I buy research-grade SS-31?

Research-grade SS-31 is sold by research peptide suppliers operating under research-use-only labeling. Quality criteria include 99%+ HPLC-MS verified purity, per-lot Certificates of Analysis, mass spectrometry identity confirmation, and verification of D-amino acid stereochemistry. Browse the OPS Peptide Science catalog for verified research-grade SS-31.

SS-31 represents a distinct category in the research peptide catalog — a structural mitochondrial peptide rather than a receptor-targeting compound. Its cardiolipin binding mechanism enables research applications spanning cardiac dysfunction, neurodegeneration, mitochondrial disease, kidney research, and skeletal muscle biology. Combined with MOTS-c’s signaling-based mitochondrial mechanism, SS-31 forms the structural half of a complementary mitochondrial peptide research pair.

For research-grade SS-31 backed by per-lot Certificates of Analysis and full HPLC-MS purity documentation, browse the OPS Peptide Science catalog, visit the OPS Peptide Science homepage for the full product overview, or verify a specific lot using its COA code.

Author: Shane Straight, Principal Chemist, OPS Peptide Science
Reviewed: Feb 2026

Peptide Education, Product Pillars, Research Protocols

MOTS-c: Complete Research Guide to the Mitochondrial-Derived Peptide

Posted on May 22, 2026May 22, 2026 by admin

22
May

Research Use Only Notice: MOTS-c is a research peptide intended for in-vitro and animal research applications only. It is not FDA-approved as a drug or therapy. Nothing in this article constitutes medical advice, treatment recommendation, or guidance for human consumption.

MOTS-c is a 16-amino-acid mitochondrial-derived peptide that has become a focal compound in modern metabolic and longevity research. Unlike most synthetic research peptides, MOTS-c is encoded by mitochondrial DNA rather than nuclear DNA — making it one of a small group of “mitochondrial-derived peptides” (MDPs) discovered relatively recently. Research has documented MOTS-c influencing insulin sensitivity, mitochondrial biogenesis, exercise-mimetic effects, and metabolic biomarker panels in animal models. This complete guide from the chemistry team at OPS Peptide Science walks through what MOTS-c is, how the mitochondrial-origin mechanism works, and where it sits in the broader research catalog.

For the foundational research-workflow protocols, see our companion guides on how to reconstitute peptides, how to inject peptides, and peptide storage and refrigeration.

What Is MOTS-c?

MOTS-c (Mitochondrial Open reading frame of the Twelve S rRNA-c) is a 16-amino-acid peptide encoded within the human mitochondrial 12S rRNA gene. The mitochondrial origin is biologically unusual — most peptides studied in research are encoded by nuclear DNA, while MOTS-c emerges from the small genome that mitochondria carry as a relic of their evolutionary origin as separate organisms.

Key facts about MOTS-c:

Chemical class — 16-amino-acid mitochondrial-derived peptide (MDP)
Molecular weight — approximately 2174 Da
Source — encoded by mitochondrial DNA (12S rRNA region), not nuclear DNA
Sequence — Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg (MRWQEMGYIFYPRKLR)
Form — typically supplied as lyophilized powder; reconstituted with bacteriostatic water
Half-life — relatively short; research models use frequent dosing
Stability — stable at -20°C as lyophilized powder for 18-24 months

The mitochondrial origin makes MOTS-c part of a small but growing class of research compounds — mitochondrial-derived peptides (MDPs). Other MDPs include humanin and the SHLP (small humanin-like peptide) family. MOTS-c is the most-studied of this group due to its metabolic effects.

MOTS-c Structure and Chemistry

MOTS-c’s structure is unusual for a peptide research compound:

16 amino acids — small enough for synthetic production at high purity
Encoded by mitochondrial 12S rRNA — an unusual coding location for a functional peptide
Naturally produced — research has documented endogenous MOTS-c in human and animal tissues, particularly in muscle
Levels respond to exercise — published research has measured MOTS-c rising with exercise, supporting the “exercise-mimetic” research framing
Levels decline with age — like many bioactive peptides, MOTS-c concentrations decrease in older subjects

The age-related decline and exercise-induced increase are what make MOTS-c interesting as a research target — both findings suggest MOTS-c is part of the cellular machinery that responds to metabolic stress and aging. Studying exogenous MOTS-c administration probes whether supplementing the natural decline produces measurable effects on the same pathways.

How MOTS-c Works in Research (Mechanism)

The MOTS-c mechanism is one of the better-characterized in modern research peptide science. Documented pathways include:

AMPK activation — MOTS-c activates AMP-activated protein kinase, a central cellular energy sensor that regulates metabolism
Folate-methionine cycle modulation — research has documented effects on one-carbon metabolism, which sits upstream of multiple cellular pathways
Mitochondrial biogenesis — induces new mitochondrial formation in research models, increasing cellular mitochondrial density
Glucose homeostasis — improves insulin sensitivity and glucose disposal in animal research models
Skeletal muscle metabolism — particularly active in muscle tissue, where MOTS-c affects glucose uptake and fatty acid oxidation
Mitochondrial-nuclear signaling — MOTS-c travels from mitochondria to nucleus, where it influences gene expression

The AMPK activation mechanism positions MOTS-c alongside compounds like metformin in mechanistic research — both activate AMPK, though through different upstream signals. The mitochondrial-nuclear signaling component is particularly novel for research peptides — MOTS-c demonstrates that mitochondria don’t just produce energy; they also send signaling molecules that influence nuclear gene expression. The published MOTS-c research literature on PubMed documents these mechanisms across the past decade of investigation.

MOTS-c Research Applications

Metabolic Research

The largest body of MOTS-c research focuses on metabolic endpoints — insulin sensitivity, glucose tolerance, lipid profiles, and broader metabolic biomarker panels. Animal models studying type 2 diabetes biology, metabolic syndrome research, and obesity-related metabolic disorders have produced consistent MOTS-c data across multiple studies.

Exercise-Mimetic Research

Because endogenous MOTS-c rises with exercise, the compound has been studied as a potential “exercise mimetic” — producing some of exercise’s metabolic effects without physical activity. Research models have documented MOTS-c effects on muscle glucose uptake, mitochondrial biogenesis, and aerobic capacity markers that overlap with exercise adaptations.

Mitochondrial Biology Research

MOTS-c is one of the central research compounds in mitochondrial biology — investigating mitochondrial-nuclear communication, mitochondrial biogenesis pathways, and mitochondrial dysfunction in aging and disease models. The compound’s mitochondrial origin makes it uniquely positioned as a research probe for mitochondrial signaling.

Aging and Longevity Research

The age-related decline in endogenous MOTS-c has driven longevity research applications. Studies have measured effects on aging-related biomarkers, healthspan endpoints, and mitochondrial function across age cohorts in animal models. MOTS-c sits alongside SS-31, NAD+ precursors, and other mitochondrial compounds in the longevity research portfolio.

Bone Research

Emerging research area — MOTS-c has been documented in bone biology research models, with effects on osteoblast activity and bone density markers. This area is smaller than the metabolic research but growing.

MOTS-c Dosing in Research Models

Research dosing patterns for MOTS-c in published studies:

Subcutaneous or intraperitoneal injection — both routes appear in published animal research
Daily dosing common — short half-life supports daily administration in most protocols
Cycle-based protocols — some research designs use 4-12 week dosing cycles with washout periods
Dose amounts — typically reported in mg/kg body weight in animal research; specific protocols vary by species and endpoint
Endpoint timelines — metabolic endpoints typically measured at 4-8 weeks; longevity endpoints over longer durations

Research protocols should reference published methodology for the specific research model. The acute vs. cumulative effect timeline distinction is addressed in our guide on how long does it take for peptides to work.

MOTS-c Storage and Stability

MOTS-c stability is comparable to other small lyophilized research peptides:

Storage Condition	Form	Stability Window
-80°C	Lyophilized powder	3-5+ years
-20°C	Lyophilized powder	18-24 months
2-8°C	Lyophilized powder	6-12 months
2-8°C	Reconstituted in BAC water	21-28 days
Room temperature	Lyophilized powder	2-4 weeks for transit

For practical storage protocols, see our guide on how long do peptides last at room temperature.

MOTS-c vs SS-31 and Other Mitochondrial Compounds

Several research compounds target mitochondrial biology. Brief comparison:

Compound	Type	Mechanism	Primary Research Focus
MOTS-c	Mitochondrial-derived peptide	AMPK activation, gene expression	Metabolism, insulin sensitivity, exercise mimicry
SS-31 (elamipretide)	Synthetic peptide	Cardiolipin binding, membrane stabilization	Cardiac, neurodegeneration, mitochondrial membrane
Humanin	Mitochondrial-derived peptide	Anti-apoptotic, cytoprotective	Neurodegeneration, cell survival
NAD+ precursors	Small molecule	NAD+ pool expansion	Sirtuin activation, aging biology

MOTS-c and SS-31 are the two most-cited mitochondrial peptides in modern research. They address different aspects of mitochondrial biology — MOTS-c affects gene expression and metabolic signaling, SS-31 stabilizes the inner mitochondrial membrane. Many research designs use them in parallel rather than as alternatives.

How to Identify Quality Research-Grade MOTS-c

Quality criteria for research-grade MOTS-c:

99%+ HPLC-MS verified purity — small peptide synthesis is generally manageable, but verification is essential for reproducible research
Per-lot Certificate of Analysis — each batch independently tested
Mass spectrometry identity confirmation — confirms molecular weight matches MOTS-c (~2174 Da)
Chain-of-custody documentation — traceable from manufacturer through fulfillment
Properly lyophilized appearance — clean white cake at the bottom of the vial
Research-use-only labeling — required by US regulations

At OPS Peptide Science, every MOTS-c vial ships with a unique BIOVIRIDIAN COA code. Customers can verify the Certificate of Analysis for their specific lot — confirming purity and identity before opening the vial.

MOTS-c Regulatory Status

MOTS-c sits in standard research-peptide regulatory territory:

Not FDA-approved — has not completed clinical trials required for human drug approval
Legal as research chemical — sold in the US for in-vitro and animal research under research-use-only labeling
Not WADA-prohibited — as of current updates, MOTS-c is not on the WADA Prohibited List, though this could change with future updates
Not DEA-scheduled — no controlled substance status
Newer compound — discovered around 2015, so regulatory frameworks are still adapting

For the complete legal framework around research peptides, see our detailed guide on are peptides illegal. According to NIH research literature, MOTS-c remains an active area of pre-clinical investigation, particularly in metabolic and longevity contexts.

FAQ

What is MOTS-c?

MOTS-c is a 16-amino-acid peptide encoded by mitochondrial DNA (specifically the 12S rRNA gene). It is one of a small class of “mitochondrial-derived peptides” (MDPs). Research has documented effects on insulin sensitivity, mitochondrial biogenesis, AMPK activation, and metabolic biomarker panels across animal research models.

What makes MOTS-c different from other peptides?

Two things. First, MOTS-c is encoded by mitochondrial DNA rather than nuclear DNA — unusual for a peptide. Second, MOTS-c demonstrates mitochondrial-nuclear signaling, where mitochondria send a peptide that influences nuclear gene expression. These features make MOTS-c a unique research probe for mitochondrial biology.

How does MOTS-c work?

MOTS-c activates AMP-activated protein kinase (AMPK), a central cellular energy sensor. AMPK activation produces downstream effects on glucose uptake, fatty acid oxidation, mitochondrial biogenesis, and metabolic gene expression. MOTS-c also modulates folate-methionine cycle activity and travels from mitochondria to nucleus to influence gene expression directly.

Is MOTS-c an exercise mimetic?

Some research uses this framing because endogenous MOTS-c levels rise with exercise. Animal research has documented overlap between MOTS-c administration and exercise-induced adaptations — muscle glucose uptake, mitochondrial biogenesis, aerobic capacity markers. This doesn’t mean MOTS-c replaces exercise; it suggests both engage similar metabolic pathways.

What’s the difference between MOTS-c and SS-31?

Both target mitochondria but through different mechanisms. MOTS-c is mitochondrial-encoded and acts through AMPK and gene expression. SS-31 is a synthetic peptide that binds cardiolipin in the mitochondrial membrane, providing structural stabilization. Research often uses them as complementary tools — MOTS-c for signaling/metabolic endpoints, SS-31 for membrane and bioenergetics endpoints.

Is MOTS-c legal in the US?

Yes — MOTS-c is legally sold in the US as a research chemical for in-vitro and animal research under research-use-only labeling. It is not FDA-approved and is not currently on the WADA Prohibited List. See our detailed guide on are peptides illegal for the full framework.

Where can I buy research-grade MOTS-c?

Research-grade MOTS-c is sold by research peptide suppliers operating under research-use-only labeling. Quality criteria include 99%+ HPLC-MS verified purity, per-lot Certificates of Analysis, mass spectrometry identity confirmation, and traceable chain-of-custody. Browse the OPS Peptide Science catalog for verified research-grade MOTS-c.

MOTS-c represents a new class of research peptides — mitochondrial-derived peptides that demonstrate mitochondria-nuclear signaling. The AMPK activation mechanism, exercise-mimetic profile, and metabolic effects make MOTS-c one of the most cited compounds in modern metabolic and longevity research. For researchers studying mitochondrial biology, insulin sensitivity, or aging endpoints, MOTS-c is among the most-referenced peptides in the modern research catalog.

For research-grade MOTS-c backed by per-lot Certificates of Analysis and full HPLC-MS purity documentation, browse the OPS Peptide Science catalog, visit the OPS Peptide Science homepage for the full product overview, or verify a specific lot using its COA code.

Author: Shane Straight, Principal Chemist, OPS Peptide Science
Reviewed: May 2026